Voyager Therapeutics (VYGR) EV to CFO (2015 - 2026)

Voyager Therapeutics has disclosed EV to CFO across 12 years of filings, most recently posting 3.8 for Q2 2026.

• In Q2 2026, EV to CFO fell 392.4% year-over-year to 3.8; the TTM figure through Jun 2026 stood at 0.81 (down 314.14% YoY), while the FY2025 annual figure was 0.27, up 90.57% from the prior year.
• EV to CFO came in at 3.8 for Q2 2026 at Voyager Therapeutics, down from 2.73 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 3.62 in Q1 2022 to a low of 273.41 in Q2 2023.
• Average EV to CFO over 5 years is 17.11, with a median of 2.31 recorded in 2026.
• Year-over-year, EV to CFO soared 600.89% in 2022 and sank 6287.8% in 2023.
• Over 5 years, EV to CFO stood at 9.53 in 2022, then surged by 37.82% to 5.93 in 2023, then surged by 49.31% to 3.0 in 2024, then jumped by 60.83% to 1.18 in 2025, then slumped by 222.67% to 3.8 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 3.8 in Q2 2026, 2.73 in Q1 2026, and 1.18 in Q4 2025.